Top psych stories of February: Antidepressant combinations, ADHD treatment updates

Healio’s most-viewed psychiatry stories in February highlight a study on antidepressant combination therapies, updates in ADHD treatments and the pandemic’s impact on those with mood and anxiety disorders.

Some antidepressant combination therapies may outperform monotherapy

Combination therapy that included an antagonist of presynaptic alpha2-autoreceptors appeared effective and safe for patients with depression who did not respond to monotherapy, according to a report published in JAMA Psychiatry. Read more.

FDA approves phase 2b/3 trial of adult ADHD treatment

The FDA has granted approval to late-stage biotech company Neurocentria Inc. to conduct a pivotal phase 2b/3 human clinical trial of its drug candidate NRCT-101SR compared with inactive placebo among adults with ADHD. Read more.

Prescription digital therapy to treat ADHD appears feasible

A study found statistically significant improvement in ADHD symptoms in children who wore the Revibe Connect device to school, according to a press release. Read more.

Children with vs. without ADHD may have modest structural brain differences

Children with ADHD exhibited modest differences on structural brain measures compared with peers without ADHD, according to results of a cross-sectional population-based study published in The Lancet Psychiatry. Read more.

Lockdown, COVID-19 incidence worsened outcomes in patients with mood, anxiety disorders

Patients with mood or anxiety disorders had significant rates of PTSD, depressive and anxiety symptoms that often persisted beyond 3 months following lockdown for the COVID-19 pandemic, according to study results. Read more.